BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses

Summary This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13...

Full description

Saved in:
Bibliographic Details
Published in:British Journal of Haematology 2022-03, Vol.196 (6), p.1329-1333
Main Authors: Avivi, Irit, Luttwak, Efrat, Saiag, Esther, Halperin, Tami, Haberman, Shira, Sarig, Ariel, Levi, Sivan, Aharon, Anat, Herishanu, Yair, Perry, Chava
Format: Article
Language:English
Subjects:
BNT162 Vaccine
BNT162b2
B‐cell non‐Hodgkin lymphoma
CD20 antigen
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
COVID‐19 vaccine booster
Hematology
Humans
humoral response
Immunization, Secondary
Lymphoma
Lymphoma, Non-Hodgkin - therapy
Monoclonal antibodies
mRNA
Non-Hodgkin's lymphoma
Patients
Prospective Studies
RNA, Messenger
SARS-CoV-2
Seroconversion
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti‐CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B‐NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B‐NHL that completed anti‐CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.18029